Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (LumOnate)

NCT07090369 PHASE1 NOT_YET_RECRUITING

This phase 1b trial is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) and pembrolizumab in patients with metastatic castration resistant prostate cancer (mCRPC).

Details

Lead sponsor	Peter MacCallum Cancer Centre, Australia
Phase	PHASE1
Status	NOT_YET_RECRUITING
Enrolment	20
Start date	Sat Nov 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Interventions

• Olaparib (300 mg BID)
• Pembrolizumab
• 177Lu-PSMA-I&T

Countries

Australia